William Love
Founder at DESTINY PHARMA PLC
Net worth: 1 M $ as of 2024-04-29
Profile
Dr. William G.
Love is a Chief Scientific Officer & Executive Director at Destiny Pharma Plc.
He is on the Board of Directors at Destiny Pharma Plc.
Dr. Love was previously employed as a Founding Member by Beam Alliance.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
DESTINY PHARMA PLC
6.83% | 2023-10-17 | 6,509,500 ( 6.83% ) | 1 M $ | 2024-04-29 |
William Love active positions
| Companies | Position | Start |
|---|---|---|
| DESTINY PHARMA PLC | Founder | 1996-03-03 |
Former positions of William Love
| Companies | Position | End |
|---|---|---|
Beam Alliance
 Beam Alliance Pharmaceuticals: MajorHealth Technology Beam Alliance is a French company that collaborates with the existing community of stakeholders to foster tangible policies and incentives for the discovery and development of novel antibacterial therapies and diagnostics. The private company is based in Paris, France. The company is aware of the problem arising from the lack of differentiation between different antimicrobials and has set up a dedicated scientific team, namely the Beam Task Force - E (BTF-E), to tackle the issue and propose solutions for better evaluating antimicrobial efficacy within a regulatory context. The company was founded by Florence Séjourné. | Corporate Officer/Principal | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| DESTINY PHARMA PLC | Health Technology |
| Private companies | 1 |
|---|---|
Beam Alliance
Beam Alliance Pharmaceuticals: MajorHealth Technology Beam Alliance is a French company that collaborates with the existing community of stakeholders to foster tangible policies and incentives for the discovery and development of novel antibacterial therapies and diagnostics. The private company is based in Paris, France. The company is aware of the problem arising from the lack of differentiation between different antimicrobials and has set up a dedicated scientific team, namely the Beam Task Force - E (BTF-E), to tackle the issue and propose solutions for better evaluating antimicrobial efficacy within a regulatory context. The company was founded by Florence Séjourné. | Health Technology |
- Stock Market
- Insiders
- William Love
